. 2015 May 1;10(5):e0126608. doi: 10.1371/journal.pone.0126608

Table 6. Excess hazards models of cancer patients by site, diagnostic interval ¹ and symptom category ² .

Cancer site / Diagnostic interval ¹	All Patients									Alert Symptoms									Non-alert Symptoms
	Univariable				Multivariable					Univariable				Multivariable					Univariable				Multivariable
	Excess Hazards Ratio	95% Confidence Interval			Excess Hazards Ratio	95% Confidence Interval			p-value	Excess Hazards Ratio	95% Confidence Interval			Excess Hazards Ratio	95% Confidence Interval			p-value	Excess Hazards Ratio	95% Confidence Interval			Excess Hazards Ratio	95% Confidence Interval			p-value
Breast^³
< 1 week	1.00				1.00					1.00				1.00					1.00
1–2 weeks	1.14	0.93	-	1.39	1.04	0.86	-	1.25	0.674	1.12	0.91	-	1.38	1.02	0.84	-	1.23	0.850	3.01	0.36	-	25.54	Convergence not achieved; too few events
3–4 weeks	0.77	0.61	-	0.98	0.85	0.68	-	1.05	0.136	0.73	0.57	-	0.93	0.80	0.64	-	1.00	0.055	3.52	0.43	-	28.52	Convergence not achieved; too few events
> 1 month	0.73	0.59	-	0.92	0.88	0.71	-	1.09	0.234	0.77	0.61	-	0.96	0.90	0.73	-	1.12	0.346	1.21	0.15	-	9.55
Colorectal ⁴
<1 month	1.00				1.00					1.00				1.00					1.00				1.00
1–2 months	0.89	0.78	-	1.00	0.94	0.82	-	1.07	0.343	0.80	0.64	-	0.99	0.86	0.68	-	1.09	0.216	0.91	0.78	-	1.05	0.94	0.79	-	1.12	0.493
3–6 months	0.83	0.74	-	0.93	0.92	0.82	-	1.04	0.174	0.71	0.57	-	0.87	0.80	0.64	-	1.00	0.053	0.79	0.69	-	0.90	0.93	0.80	-	1.08	0.349
>6 months	0.98	0.87	-	1.11	0.93	0.81	-	1.07	0.326	1.07	0.82	-	1.41	0.99	0.74	-	1.32	0.961	0.80	0.69	-	0.92	0.85	0.72	-	1.00	0.049
Lung ⁵
<1 month	1.00				1.00					1.00				1.00					1.00				1.00
1–2 months	0.97	0.89	-	1.06	1.02	0.93	-	1.11	0.648	0.87	0.70	-	1.08	0.99	0.78	-	1.25	0.919	0.96	0.87	-	1.05	1.00	0.91	-	1.11	0.916
3–6 months	0.84	0.78	-	0.91	0.90	0.84	-	0.98	0.014	0.71	0.56	-	0.90	0.79	0.62	-	1.02	0.069	0.81	0.74	-	0.88	0.87	0.80	-	0.95	0.001
>6 months	0.89	0.82	-	0.96	0.87	0.80	-	0.94	0.001	0.93	0.69	-	1.27	0.97	0.70	-	1.36	0.872	0.83	0.76	-	0.90	0.81	0.74	-	0.89	0.000
Prostate ⁶
<1 month	1.00				1.00														1.00				1.00
1–2 months	0.49	0.33	-	0.73	0.64	0.42	-	0.98	0.042	0.52	0.17	-	1.63	Convergence not achieved; high survival in last group					0.45	0.30	-	0.69	0.51	0.32	-	0.82	0.006
3–6 months	0.40	0.27	-	0.58	0.72	0.49	-	1.05	0.084	0.51	0.17	-	1.54	Convergence not achieved; high survival in last group					0.34	0.23	-	0.51	0.58	0.38	-	0.88	0.010
>6 months	0.16	0.07	-	0.38	0.45	0.27	-	0.75	0.002	0.38	0.07	-	2.03						0.12	0.05	-	0.33	0.37	0.21	-	0.64	0.000

¹time between first symptom presentation in primary care and diagnosis

²symptoms were categorized as alert or non-alert based on the NICE guidelines

³adjusted for age, sex, ethnicity, level of deprivation, morphology, tumour differentiation, number of consultations, treatment and comorbidity

⁴adjusted for age, sex, ethnicity, Duke stage, level of deprivation, morphology, tumour differentiation, tumour subsite, number of consultations, treatment and comorbidity

⁵adjusted for age, sex, ethnicity, tumour grade, smoking status, level of deprivation, morphology, number of consultations, treatment and comorbidity

⁶adjusted for age (15–54, 55–64, 64–74, 75+), ethnicity, tumour differentiation, level of deprivation, morphology, number of consultations, treatment and comorbidity

Table 6. Excess hazards models of cancer patients by site, diagnostic interval 1 and symptom category 2 .

Table 6. Excess hazards models of cancer patients by site, diagnostic interval ¹ and symptom category ² .